Literature DB >> 18449551

Survival analysis between patients with invasive ductal and invasive lobular breast cancer.

Darius Dian1, Hannes Herold, Ioannis Mylonas, Christoph Scholz, Wolfgang Janni, Harald Sommer, Klaus Friese.   

Abstract

OBJECTIVE: Differences in overall survival (OS) and disease-free survival (DFS) between patients with invasive ductal (IDC) and invasive lobular breast cancer (ILC) are controversial. STUDY
DESIGN: The study population was selected from a database of 5,689 female patients with invasive breast cancer. In order to focus on the impact of tumour histology, all primary metastatic patients and patients with adjuvant chemotherapy or anti-hormonal treatment were excluded. Only patients with pure invasive lobular and invasive ductal histology were included.
RESULTS: Multivariate survival analyses of 2,058 eligible patients confirmed tumour histology as an independent prognostic factor for OS in invasive breast cancer (p = 0.046) but not for DFS (p = 0.599). Kaplan-Meier survival analysis of OS between IDC and ILC patients showed a statistically significantly better OS for patients with ILC (p = 0.0302). DFS was not statistically different (p = 0.6659) between IDC and ILC. Univariate survival analyses of tumour size, tumour grading and nodal status in our study population were highly statistically significant for OS and DFS (p < 0.0000).
CONCLUSION: Patients in our study population with ILC have significantly better OS than patients with IDC. Differences in DFS are not statistically significant.

Entities:  

Mesh:

Year:  2008        PMID: 18449551     DOI: 10.1007/s00404-008-0662-z

Source DB:  PubMed          Journal:  Arch Gynecol Obstet        ISSN: 0932-0067            Impact factor:   2.344


  8 in total

1.  Breast cancer survival by molecular subtype: a population-based analysis of cancer registry data.

Authors:  Saber Fallahpour; Tanya Navaneelan; Prithwish De; Alessia Borgo
Journal:  CMAJ Open       Date:  2017-09-25

2.  Risk of mortality by histologic type of breast cancer in the United States.

Authors:  Christopher I Li
Journal:  Horm Cancer       Date:  2010-06       Impact factor: 3.869

3.  Recurrent invasive lobular carcinoma presenting as a ruptured breast implant.

Authors:  Maikel Botros; Kenneth Chang; Robert Miller; Sunil Krishnan; Matthew Iott
Journal:  Radiol Oncol       Date:  2011-10-08       Impact factor: 2.991

4.  Differential diagnosis of breast cancer using quantitative, label-free and molecular vibrational imaging.

Authors:  Yaliang Yang; Fuhai Li; Liang Gao; Zhiyong Wang; Michael J Thrall; Steven S Shen; Kelvin K Wong; Stephen T C Wong
Journal:  Biomed Opt Express       Date:  2011-07-05       Impact factor: 3.732

5.  Survival Outcomes of Breast-Conserving Therapy versus Mastectomy in Early-Stage Breast Cancer, Including Centrally Located Breast Cancer: A SEER-Based Study.

Authors:  Tianshui Yu; Weilun Cheng; Ting Wang; Ziang Chen; Yu Ding; Jianyuan Feng; Yunqiang Duan; Anbang Hu; Mingcui Li; Hanyu Zhang; Yanling Li; Fei Ma; Baoliang Guo
Journal:  Breast J       Date:  2022-08-27       Impact factor: 2.269

6.  Comparison of breast cancer to healthy control tissue discovers novel markers with potential for prognosis and early detection.

Authors:  Michèl Schummer; Ann Green; J David Beatty; Beth Y Karlan; Scott Karlan; Jenny Gross; Sean Thornton; Martin McIntosh; Nicole Urban
Journal:  PLoS One       Date:  2010-02-09       Impact factor: 3.240

7.  The role of histological subtype in hormone receptor positive metastatic breast cancer: similar survival but different therapeutic approaches.

Authors:  Dorien Lobbezoo; Wilfred Truin; Adri Voogd; Rudi Roumen; Gerard Vreugdenhil; Marcus Wouter Dercksen; Franchette van den Berkmortel; Tineke Smilde; Agnes van de Wouw; Roel van Kampen; Johanna van Riel; Natascha Peters; Petronella Peer; Vivianne C G Tjan-Heijnen
Journal:  Oncotarget       Date:  2016-05-17

8.  Decreased Survival of Invasive Ductal Breast Cancer Patients With Two Macrometastatic Lymph Nodes Among Few Resected Ones: Should Current Sentinel-Lymph-Node Guidelines Be Revised?

Authors:  Felipe A C Luz; Rogério A Araújo; Marcelo J B Silva
Journal:  Front Oncol       Date:  2021-07-19       Impact factor: 6.244

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.